APA (7th ed.) Citation

de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., . . . Castellano, D. (2019). Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The New England journal of medicine, 381(26), 2506-2518. https://doi.org/10.1056/NEJMoa1911206

Chicago Style (17th ed.) Citation

de Wit, Ronald, et al. "Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer." The New England Journal of Medicine 381, no. 26 (2019): 2506-2518. https://doi.org/10.1056/NEJMoa1911206.

MLA (9th ed.) Citation

de Wit, Ronald, et al. "Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer." The New England Journal of Medicine, vol. 381, no. 26, 2019, pp. 2506-2518, https://doi.org/10.1056/NEJMoa1911206.